Bayer : Decline in CS’ earnings could be more pronounced than anticipated – pressure on Pharma to remain
>Pressure on earnings in 2023 – legal risks have become more predictable - While good FY 2022 were clearly driven by a strong CropScience (CS) business, we do not share the company’s optimism for 2023 that glyphosate prices remain above 2021 levels. Additionally, new launches in the Pharma division are not expected to compensate already for declining blockbuster earnings and Consumer Health’s (CH) profitability should be burdened by inflation. We are therefore cutting...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.